YOLFTbeta
Allogene Therapeutics Inc

Allogene Therapeutics Inc

ALLO · NASDAQ · Healthcare / Biotechnology

0.8387USD+0.01 (+1.41%)

Price History

Full chart

Market Stats

Previous Close0.827
Open0.839
Day Range0.8201 – 0.8654
52-Week Range1.04 – 4.46
Volume11.66M
Market Cap570.06M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.66
Dividend Yield0.00%
Beta0.48
50-Day Avg1.90
200-Day Avg1.99

About

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Zachary J. Roberts M.D., Ph.D.
  • Employees150
  • Headquarters210 East Grand Avenue, South San Francisco, CA, United States, 94080, USA
  • Websitehttps://allogene.com

Leadership

  • Dr. Arie S. Belldegrun F.A.C.S., M.D.Co-Founder & Executive Chairman · b. 1949
  • Dr. Zachary J. Roberts M.D., Ph.D.President, CEO & Director · b. 1978
  • Mr. Joshua A. KazamCo-Founder & Director · b. 1977
  • Dr. David D. Chang M.D., Ph.D.Co-Founder & Director · b. 1960
  • Mr. Geoffrey M. ParkerExecutive VP & CFO · b. 1965
  • Mr. Benjamin M. BeneskiSenior VP & Chief Technical Officer · b. 1977
  • Mr. Earl M. Douglas Esq.Senior VP, General Counsel, Compliance Officer & Corporate Secretary · b. 1963
  • Ms. Susan R. LundeenChief People Officer · b. 1966
  • Ms. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy Officer
  • Ms. Annie YoshiyamaSVP & Corporate Controller · b. 1984

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00038.34M38.49M243.00K95.00K22.00K0
Growth (%)----+0.38%-99.37%-60.91%-76.84%-100.00%
Cost of Revenue01.50M5.03M11.54M13.06M16.73M14.20M13.64M12.36M
Gross Profit0-1.50M-5.03M-11.54M38.49M243.00K95.00K22.00K-12.36M
Gross Margin----30.10%100.00%100.00%100.00%100.00%-
Operating Expense2.00K191.34M196.98M246.70M294.28M335.69M327.83M273.22M194.57M
Operating Income-2.00K-192.84M-202.01M-258.24M-255.79M-335.45M-327.74M-273.20M-206.93M
Operating Margin----673.47%-664.58%-138044.86%-344986.32%-1241813.64%-
EBITDA22.00K-206.76M-179.90M-250.66M-245.34M-321.15M-313.07M-243.33M-177.45M
EBITDA Margin----653.69%-637.42%-132162.14%-329543.16%-1106031.82%-
Net Income-2.00K-211.50M-184.59M-233.47M-244.84M-329.81M-327.26M-257.59M-190.89M
Net Income Margin----608.87%-636.12%-135726.34%-344489.47%-1170863.64%-
R&D151.86M151.86M144.53M192.99M220.18M256.39M242.91M192.30M150.15M
R&D as % of Total Revenue---503.29%572.05%105509.05%255698.95%874086.36%-
Interest Expense03.36M5.03M9.16M10.45M17.11M17.11M181.00K1.07M
Interest Expense % of Total Revenue---23.90%27.16%7041.98%18012.63%822.73%-

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets0773.86M717.80M1.23B1.05B821.58M642.84M548.71M415.90M
Total Liabilities2.00K70.69M88.78M148.21M125.63M154.70M130.60M126.53M123.36M
Total Equity-2.00K703.16M629.02M1.08B925.20M666.88M512.23M422.18M292.54M
Cash0721.35M175.13M183.35M173.31M61.90M83.16M75.22M51.69M
Total Debt-34.46M53.03M53.78M73.13M101.12M95.12M90.76M83.25M
Net Debt--686.89M-122.10M-129.57M-100.19M39.22M11.97M15.54M31.57M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-44.65M-44.65M-137.35M-115.09M-184.81M-220.52M-237.73M-200.30M-149.25M
Investing Cash Flow-632.80M-632.80M164.08M-505.12M163.66M106.16M163.29M75.69M95.56M
Financing Cash Flow771.18M771.18M58.96M633.59M11.96M2.95M95.69M116.67M30.16M
Capital Expenditure5.33M3.23M50.79M65.96M21.45M5.19M1.52M694.00K386.00K
Free Cash Flow--47.89M-188.14M-181.05M-206.26M-225.71M-239.25M-200.99M-149.63M
FCF to OCF-107.24%136.98%157.31%111.60%102.35%100.64%100.35%100.26%

Earnings

Report DateAug 29, 2018Nov 21, 2018Mar 8, 2019May 7, 2019Aug 7, 2019Nov 5, 2019Feb 27, 2020May 6, 2020Aug 5, 2020Nov 4, 2020Feb 25, 2021May 5, 2021Aug 4, 2021Nov 4, 2021Feb 23, 2022May 4, 2022Aug 9, 2022Nov 2, 2022Feb 28, 2023May 3, 2023Aug 2, 2023Nov 2, 2023Mar 14, 2024May 13, 2024Aug 7, 2024Nov 7, 2024Mar 12, 2025May 13, 2025Aug 13, 2025Nov 6, 2025Mar 4, 2026May 13, 2026Aug 12, 2026Nov 5, 2026
EPS Estimate0.00-0.39-0.25-0.43-0.44-0.54-0.68-0.58-0.54-0.55-0.56-0.49-0.55-0.56-0.60-0.58-0.61-0.65-0.70-0.62-0.59-0.52-0.45-0.41-0.35-0.33-0.32-0.29-0.27-0.23-0.23-0.18-0.16-0.13
EPS Actual-2.23-0.43-0.37-0.32-0.41-0.50-0.58-0.50-0.53-0.52-0.53-0.25-0.53-0.57-0.54-0.56-0.52-0.58-0.66-0.68-0.53-0.37-0.43-0.38-0.32-0.27-0.28-0.28-0.22-0.19-0.17-0.18-0.13-
Surprise--10.26%-48.00%25.58%6.82%7.41%14.71%13.79%1.85%5.45%5.36%48.98%3.64%-1.79%10.00%3.45%14.75%10.77%5.71%-9.68%10.17%28.85%4.44%7.32%8.57%18.18%13.42%3.45%18.52%17.39%24.61%0.00%18.75%-
Timing-After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap570.06M
Enterprise Value316.45M
Trailing P/E0.00
Forward P/E0.00
Price / Sales122.86
Price / Book1.33
EPS-0.66
Book Value1.26
Revenue (TTM)4.64M
Gross Profit (TTM)-117.88M
EBITDA-168.65M
Profit Margin0.00%
Operating Margin-1011.21%
Return on Equity-42.39%
Return on Assets-22.08%
Shares Outstanding345.49M
Shares Float262.41M
Beta0.48
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 14 analystsTarget 9.00
  • Strong Buy
    8
  • Buy
    4
  • Hold
    2

Ownership Breakdown

Institutions
88.00%
Insiders
11.03%
Retail / Other
0.97%

Top Institutional Holders

  • Pfizer Inc
    22.03M6.38%
  • BlackRock Inc
    19.09M5.53%
  • TPG GP A, LLC
    18.72M5.42%
  • Sio Capital Management, LLC
    13.32M3.86%
  • PRIMECAP Management Company
    13.12M3.80%
  • Citadel Advisors Llc
    10.09M2.92%
  • State Street Corp
    8.66M2.51%
  • Two Sigma Investments LLC
    7.78M2.25%
  • Vanguard Capital Management, LLC
    6.92M2.00%
  • T. Rowe Price Associates, Inc.
    5.38M1.56%
  • GordonMD Global Investments LP
    5.30M1.53%
  • Patient Square Capital LP
    5.05M1.46%
  • Aberdeen Group PLC
    5.00M1.45%
  • Millennium Management LLC
    4.84M1.40%
  • D. E. Shaw & Co LP
    4.71M1.36%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    12.81M3.71%
  • Fidelity Select Biotechnology
    10.35M2.99%
  • Vanguard Capital Opportunity Inv
    9.39M2.72%
  • Vanguard MStar Total Stk Mkt Idx Invest
    8.67M2.51%
  • iShares Russell 2000 ETF
    6.81M1.97%